What dose adjustments are recommended for irinotecan based on a patient’s UGT1A1 genotype (including *28 and *6 alleles)?

UGT1A1 Genotype-Guided Irinotecan Dosing

*For patients with UGT1A128/*28, *6/*6, or compound heterozygous 6/28 genotypes, reduce the starting dose of irinotecan by at least one dose level (approximately 30% reduction), as this significantly decreases severe neutropenia and diarrhea while maintaining therapeutic efficacy. 1

Genotype-Specific Dose Adjustments

For Homozygous or Compound Heterozygous Poor Metabolizers (*28/*28, *6/*6, or *6/*28):

Reduce starting dose by at least one level:

• Weekly regimen: Start at 100 mg/m² instead of 125 mg/m² (20% reduction)
• Every 3-week regimen: Start at 300 mg/m² instead of 350 mg/m² (14% reduction)
• Higher intensity regimens: Consider 30% dose reduction 1

This recommendation is based on the FDA drug label which explicitly states to "consider a reduction in the starting dose by at least one level" for these genotypes 1. Recent prospective data demonstrates this approach reduces febrile neutropenia from 24% to 6.5% in poor metabolizers while maintaining comparable efficacy to normal metabolizers receiving full doses 2.

For Heterozygous Intermediate Metabolizers (*1/*28 or *1/*6):

No initial dose reduction required - start with standard dosing and monitor closely 1. The 1.8-fold increased neutropenia risk in heterozygotes is not statistically significant 3.

For Wild-Type Normal Metabolizers (*1/*1):

Use standard dosing without modification 1.

Critical Genotypes to Test

*Test for both UGT1A128 AND 6 alleles*, particularly in Asian populations where *6 is more prevalent than *28 4, 5. The *6 allele causes similar or greater toxicity risk:

• UGT1A1*6 homozygotes/compound heterozygotes show significantly higher SN-38 exposure and 73.3% incidence of grade ≥3 neutropenia versus 38.1% in wild-type patients 5
• In Asian populations, *6/*6 occurs in 2.5%, *28/*28 in 1.9%, and *6/*28 compound heterozygosity in 4.9% 5

Toxicity Risks by Genotype (Without Dose Adjustment)

At standard irinotecan doses:

**Poor Metabolizers (28/28):

• 38% severe neutropenia (3.5-fold increased risk)
• 27% severe diarrhea (1.6-fold increased risk, not statistically significant)
• 70% tumor response rate (1.7-fold increased, suggesting standard doses may overdose these patients) 3

**Heterozygotes (1/28):

• 18% severe neutropenia (1.8-fold increased risk, not statistically significant)
• 27% severe diarrhea 3

**Wild-Type (1/1):

• 9.8% severe neutropenia (baseline)
• 18% severe diarrhea 3

Clinical Implementation Algorithm

1. Obtain UGT1A1 genotyping BEFORE initiating irinotecan - testing is FDA-cleared and considered "essential" by Dutch guidelines 6

2. Adjust starting dose based on genotype:

   • Poor metabolizers (*28/*28, *6/*6, *6/*28): Reduce by 30%
   • Intermediate metabolizers (*1/*28, *1/*6): Standard dose
   • Normal metabolizers (*1/*1): Standard dose

3. **For patients with AA genotype (*6/*6)**: Consider alternative chemotherapy (e.g., paclitaxel) as irinotecan may not be suitable even with dose reduction 4

4. Subsequent dose modifications: Adjust based on individual tolerance using standard toxicity-based algorithms 1

Important Caveats

The dose-response paradox: Poor metabolizers have higher tumor response rates (70% vs 41%) at standard doses 3, suggesting they achieve therapeutic drug levels at lower doses. This supports dose reduction without compromising efficacy.

Lower-dose regimens (<150 mg/m²): The association between UGT1A1 genotype and neutropenia may be less pronounced at doses below 150 mg/m², though clinical effectiveness at these lower doses remains unclear 3.

Cost-effectiveness: Genotype-guided dosing saves €183 per patient by preventing severe toxicities 2.

Pharmacokinetic validation: Dose-finding studies demonstrate that genotype-guided dosing achieves similar SN-38 exposure across genotypes, with MTDs of 850 mg (*1/*1), 700 mg (*1/*28), and 400 mg (*28/*28) every 3 weeks 7.

Guideline Controversy

The 2009 EGAPP Working Group found "no evidence to support clinical utility" of routine UGT1A1 testing 3, arguing that benefits of reduced toxicity may not outweigh potential harms of reduced tumor response. However, this conclusion predates:

• FDA label updates mandating dose consideration for poor metabolizers 1
• Prospective safety data demonstrating significant toxicity reduction 2
• Dutch guidelines designating testing as "essential" 6
• Recognition of the *6 allele's importance in Asian populations 4, 5

The current standard of care prioritizes patient safety through genotype-guided dose reduction in poor metabolizers, as severe neutropenia and diarrhea significantly impact quality of life and mortality risk, while dose-reduced poor metabolizers still achieve therapeutic drug exposure.